Johnson & Johnson Shares Jump Toward the Record High After FDA Approval; UBS Lifts Target to $320

Johnson & Johnson shares rose as much as 2.7% on Wednesday, trading near $278.63 in New York and extending a yearlong rally toward a record. The stock was up $7.44 from Tuesday’s close of $271.19 as of 10:01 a.m. Eastern, with intraday prints topping the prior peak near $276.47 from Aug. 19. The advance followed a late-August FDA approval for a rare-disease use of the company’s immunology drug Imaavy, along with a Wall Street price-target increase that valued shares above the new high. Based in New Brunswick, New Jersey, the company has gained more than 50% over 12 months; its 52-week low was $173.33 in September 2025. The FDA approval on Aug. 24 covers warm autoimmune hemolytic anemia in patients 12 and older. The 24-week trial showed 24% of patients on the 30 mg/kg dose reached a durable hemoglobin response versus 8% on placebo, with the 15 mg/kg arm not beating placebo. Imaavy is infused every four weeks.